Valneva SE (VALN) Non-Current Deffered Revenue (2021 - 2026)
Valneva SE (VALN) posted quarterly Non-Current Deffered Revenue of $485906.5 for Q1 2026, down 88.62% year-on-year from $4.3 million in Q1 2025, and down 1.16% on a QoQ basis from $491596.2 in Q4 2025.
Valneva SE (VALN) Non-Current Deffered Revenue (2021 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Non-Current Deffered Revenue for 6 consecutive years, with $485906.5 the latest figure, recorded in Q1 2026.
- Quarterly Non-Current Deffered Revenue fell 88.62% year-over-year to $485906.5 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $485906.5 (down 88.62% YoY) and the FY2025 annual result came in at $491596.2, down 85.65% from the prior year.
- Non-Current Deffered Revenue declined to $485906.5 in Q1 2026 per VALN's latest filing, from $491596.2 in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for VALN reached as high as $139.4 million in Q1 2022 and fell as low as -$6.0 million in Q4 2022.
- A 5-year average of $20.3 million and a median of $6.0 million in 2024 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue slumped 210.55% — and 2023, when it surged 208.7%.
- Year by year, Non-Current Deffered Revenue stood at -$6.0 million in 2022, then soared by 208.7% to $6.5 million in 2023, then tumbled by 47.17% to $3.4 million in 2024, then sank by 85.65% to $491596.2 in 2025, then slipped by 1.16% to $485906.5 in 2026.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $485906.5, $491596.2, and $481354.7 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn | 485,906.47 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 485,906.47 |
| Dec 31, 2025 | 491,596.25 |
| Sep 30, 2025 | 481,354.66 |
| Jun 30, 2025 | 591,736.22 |
| Mar 31, 2025 | 4.27 Mn |
| Dec 31, 2024 | 3.43 Mn |
| Sep 30, 2024 | 1.09 Mn |
| Jun 30, 2024 | 6.03 Mn |
| Mar 31, 2024 | 6.02 Mn |
| Dec 31, 2023 | 6.48 Mn |
| Sep 30, 2023 | 15.18 Mn |
| Jun 30, 2023 | 13.18 Mn |
| Mar 31, 2023 | 10.42 Mn |
| Dec 31, 2022 | -5.96 Mn |
| Sep 30, 2022 | 7.86 Mn |
| Jun 30, 2022 | 136.23 Mn |
| Mar 31, 2022 | 139.37 Mn |
| Dec 31, 2021 | 5.40 Mn |